<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852024000200005</article-id>
<article-id pub-id-type="doi">10.48193/8s9rt103</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Pioglitazona y su relación con el cáncer de vejiga. Revisión sistemática]]></article-title>
<article-title xml:lang="en"><![CDATA[Pioglitazone and its relation to bladder cancer. Systematic review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz Brito]]></surname>
<given-names><![CDATA[Marco Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz Brito]]></surname>
<given-names><![CDATA[Marco Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cisneros Espín]]></surname>
<given-names><![CDATA[Franklin Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guerrero-Ortiz]]></surname>
<given-names><![CDATA[Fabricio Byron]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Católica de Cuenca  ]]></institution>
<addr-line><![CDATA[Azuay Cuenca]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2024</year>
</pub-date>
<volume>84</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852024000200005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852024000200005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852024000200005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Descripción: el cáncer de vejiga es un problema de salud pública ya que se encuentra entre los 10 tipos de cánceres más frecuentes en hombres, está relacionado con múltiples factores de riesgo entre los que destaca la pioglitazona.  Relevancia:  existe controversia de los diferentes estudios en sus resultados respecto a la verdadera relación entre pioglitazona y cáncer de vejiga, ya que unos apoyan su relación, mientras en otros no existe asociación.  Conclusiones:  se necesitan aún más estudios que permitan establecer de manera definitiva la verdadera relación ya que la información actual es contradictoria.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Description:  bladder cancer is a public health problem since it is among the 10 most frequent cancers in men, it is related to multiple risk factors among which Pioglitazone stands out.  Relevance:  there is controversy in the results of the different studies regarding the true relationship between Pioglitazone and bladder cancer, since some support its relationship, while in others there is no association.  Conclusions:  more studies are still needed to definitively establish the true relationship since the current information is contradictory.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Bladder cancer]]></kwd>
<kwd lng="en"><![CDATA[risk factor]]></kwd>
<kwd lng="en"><![CDATA[pioglitazone]]></kwd>
<kwd lng="es"><![CDATA[Cáncer de vejiga]]></kwd>
<kwd lng="es"><![CDATA[factor de riesgo]]></kwd>
<kwd lng="es"><![CDATA[pioglitazona]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Organizacón Panamericana de la Salud</collab>
<source><![CDATA[Cáncer]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Centros para el Control y la Prevención de Enfermedades</collab>
<source><![CDATA[Cáncer de vejiga]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>Centros para el Control y la Prevención de Enfermedades</collab>
<source><![CDATA[Datos y estadísticas del cáncer]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>International Agency for Research on Cancer</collab>
<source><![CDATA[Cancer statistics in Mexico]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corral Cordero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cueva Ayala]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Yépez Maldonado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tarupi Montenegro]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tendencias en incidencia y mortalidad por cáncer durante tres decadas en Quito - Ecuador]]></article-title>
<source><![CDATA[Colombia Médica]]></source>
<year>2018</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-41</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>American Cancer Society</collab>
<source><![CDATA[Factores de riesgo de cáncer de vejiga]]></source>
<year>2017</year>
<publisher-name><![CDATA[American Cancer Society]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>Agencia Española de, Medicamentos y Productos Sanitarios (AEMPS)</collab>
<source><![CDATA[Pioglitazona: resultados de la evaluación europea sobre su posible asociación con el cáncer de vejiga]]></source>
<year>2011</year>
<publisher-name><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrillo]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asociación Latinoamericana de Diabetes (2015). Guías ALAD sobre el diagnóstico, control y tratamiento de la diabetes mellitus tipo 2 con medicina basada en evidencia: Asociación Latinoamericana de Diabetes]]></article-title>
<source><![CDATA[Revista Psicología]]></source>
<year>2015</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>167</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kojdamanian Favetto]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía NICE 2022: actualización en el manejo de la diabetes mellitus tipo 2 en personas adultas]]></article-title>
<source><![CDATA[Evidencia, actualizacion en la práctica ambulatoria]]></source>
<year>2022</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e007015</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Food &amp; Drung Admistration</collab>
<source><![CDATA[2016 Comunicaciones de la FDA sobre la seguridad de los medicamentos]]></source>
<year>2019</year>
<publisher-name><![CDATA[FDA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nicolau Ramis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Masmiquel Comas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Los nuevos antidiabéticos en el punto de mira... ¿razones de seguridad o caza de brujas?]]></article-title>
<source><![CDATA[Endocrinol. nutr]]></source>
<year>2012</year>
<volume>59</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>Food &amp; Drung Admistration</collab>
<source><![CDATA[Una revisión actualizada de la FDA concluye que el uso del medicamento pioglitazona para la diabetes tipo 2 puede estar vinculado a un aumento del riesgo de cáncer de vejiga]]></source>
<year>2019</year>
<publisher-name><![CDATA[FDA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colmers]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
<name>
<surname><![CDATA[Bowker]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Majumdar]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[JA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis]]></article-title>
<source><![CDATA[Canadian Medical Association Journal]]></source>
<year>2012</year>
<volume>184</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>E675-83</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piccinni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Motola]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Marchesini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Poluzzi]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2011</year>
<volume>34</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1369-71</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>Instituto Nacional del Cáncer</collab>
<source><![CDATA[Causas y factores de riesgo del cáncer de vejiga]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hedderson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bilker]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Quesenberry]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2011</year>
<volume>34</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>916-22</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filipova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Uzunova]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kalinov]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vekov]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis]]></article-title>
<source><![CDATA[Diabetes Therapy]]></source>
<year>2017</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>705-26</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[McKenzie]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Bossuyt]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Boutron]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Mulrow]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas]]></article-title>
<source><![CDATA[Revista Española de Cardiología]]></source>
<year>2021</year>
<volume>74</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>790-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<collab>Critical Appraisal Skills Programme Español</collab>
<source><![CDATA[Lista de verificación de revisión sistemática]]></source>
<year>2020</year>
<publisher-name><![CDATA[Critical Appraisal Skills Programme Español]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<collab>Critical Appraisal Skills Programme Español</collab>
<source><![CDATA[Instrumentos para la lectura crítica]]></source>
<year>2015</year>
<publisher-name><![CDATA[Critical Appraisal Skills Programme Español]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug&#8217;s effect on cardiovascular disease and non-alcoholic steatohepatitis]]></article-title>
<source><![CDATA[Diabetes Research and Clinical Practice]]></source>
<year>2018</year>
<volume>135</volume>
<page-range>102-10</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Afreen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kazmi]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bladder Cancer In Patients With Type 2 Diabetes Treated With Pioglitazone, A Comparative Study]]></article-title>
<source><![CDATA[Journal of Ayub Medical College, Abbottabad: JAMC]]></source>
<year>2018</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>356-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agrawal]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gautam]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nigam]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Pursnani]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Farooqui]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone]]></article-title>
<source><![CDATA[Perspectives in Clinical Research]]></source>
<year>2021</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-13</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adil]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Ghosh]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Venkata]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Kandhare]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic literature review and meta-analysis of observational studies using real-world data]]></article-title>
<source><![CDATA[Clinical Epidemiology and Global Health]]></source>
<year>2018</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>61-8</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garry]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Buse]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Lund]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Pate]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Stürmer]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes]]></article-title>
<source><![CDATA[Diabetes, Obesity &amp; Metabolism]]></source>
<year>2018</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>129-40</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ying]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Cancer Management and Research]]></source>
<year>2018</year>
<volume>10</volume>
<page-range>1627-38</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malhotra]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hiteshi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Khalkho]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Malik]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bhadada]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Bhansali]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bladder cancer with pioglitazone: A case-control study]]></article-title>
<source><![CDATA[Diabetes &amp; Metabolic Syndrome]]></source>
<year>2022</year>
<volume>16</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>102637</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramezannezhad]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Khosravifarsani]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association between pioglitazone consumption and incidence of bladder cancer in type II diabetic patients: a systematic review and meta-analysis of observational studies]]></article-title>
<source><![CDATA[Journal of Nephropathology]]></source>
<year>2023</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhushan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Prakash]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[GN.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis]]></article-title>
<source><![CDATA[Clinical Therapeutics]]></source>
<year>2019</year>
<volume>41</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2252-62</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zhai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pioglitazone and bladder cancer risk: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Cancer Medicine]]></source>
<year>2018</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1070-80</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinha]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ghosal]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials]]></article-title>
<source><![CDATA[Scientific Reports]]></source>
<year>2020</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15781</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[YR]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[PY]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone]]></article-title>
<source><![CDATA[Journal of Personalized Medicine]]></source>
<year>2021</year>
<volume>11</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>828</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ripamonti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Azoulay]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Abrahamowicz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Platt]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Suissa]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of observational studies of the association between pioglitazone use and bladder cancer]]></article-title>
<source><![CDATA[Diabetic Medicine: A Journal of the British Diabetic Association]]></source>
<year>2019</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-35</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
